Pomerantz Law Firm Investigates Biogen Inc. for Potential Securities Fraud
The Pomerantz Law Firm is investigating potential securities fraud or other unlawful business practices by Biogen and its officers following the release of disappointing clinical trial results, which caused a 6.43% drop in stock price on May 14, 2026.
Tickers: $BIIB
Topics: Biogen investor claims Phase 2 clinical trial results stock price drop